Hong Kong Insurance Stock News

The board of directors of Hansoh Pharmaceutical Group announced that China's National Medical Products Administration has accepted the New Drug Application for HS-10365 capsules, a selective RET inhibitor for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer. This regulatory milestone not only reflects progress in Hansoh’s oncology pipeline, but also highlights the company’s potential to address significant unmet needs in lung cancer...

Impro Precision Industries (SEHK:1286) just posted a strong year-on-year jump in third quarter revenue, with standout gains in its diversified industrials and AI-related segments. The company’s positive sales outlook continues to draw attention from investors. See our latest analysis for Impro Precision Industries. Momentum has clearly shifted in Impro Precision Industries’ favor, with the share price climbing 12.87% over the past month and surging 65% in the last quarter. That is part of a...

Key Insights Significant control over TUHU Car by individual investors implies that the general public has more power...

The Veeko International Holdings Limited ( HKG:1173 ) share price has softened a substantial 35% over the previous 30...

Those holding Magnus Concordia Group Limited ( HKG:1172 ) shares would be relieved that the share price has rebounded...

Oi Wah Pawnshop Credit Holdings Limited ( HKG:1319 ) will increase its dividend on the 28th of November to HK$0.01...

Those holding Best Food Holding Company Limited ( HKG:1488 ) shares would be relieved that the share price has...

China Environmental Technology and Bioenergy Holdings Limited ( HKG:1237 ) shareholders won't be pleased to see that...

Fengyinhe Holdings Limited ( HKG:8030 ) shares have continued their recent momentum with a 38% gain in the last month...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Crystal International Group's (HKG:2232) stock is up by a considerable 18% over the past three months. Since the market...

CARsgen Therapeutics Holdings (SEHK:2171) has caught investor attention with an active streak of recent updates. In the past days, the company rolled out promising clinical trial results and approved a sizeable share buyback program. See our latest analysis for CARsgen Therapeutics Holdings. Despite a steep 12% decline in the past month, CARsgen’s share price has surged 76% year to date, reflecting renewed optimism driven by its clinical breakthroughs and buyback momentum. The company’s one...

Moon (SEHK:1723) remains unprofitable, with losses accelerating at a rapid pace of 74.3% per year over the last five years and no improvement in margins. The company’s shares are trading at a steep Price-to-Sales Ratio of 7.4x, far surpassing both its peer average of 0.1x and the broader Hong Kong electronic industry average of 0.5x. This implies that the current market price of HK$3.06 is well above the estimated fair value of HK$0.23. With no signs of profit growth, continued share...

Kinetic Development Group recently increased its stake in MC Mining to approximately 40.13% through completed share subscription tranches, with ambitions to reach a 51% holding as the Makhado Project in South Africa advances towards key infrastructure milestones by December 2025. This move highlights Kinetic’s intention to deepen its involvement in the mining sector and signals confidence in the development potential of the Makhado asset. We'll examine how Kinetic's push for majority...

In recent announcements by CSPC Pharmaceutical Group, the company received approval to begin clinical trials for its innovative siRNA drug SYH2061 targeting complement component C5, and its co-developed HER2-targeting antibody-drug conjugate JSKN003 was granted Breakthrough Therapy Designation in China for advanced colorectal cancer. These regulatory milestones highlight CSPC’s expanding capabilities in developing first-in-class treatments addressing significant unmet clinical needs within...

Chery Automobile (SEHK:9973) has been trading in a relatively narrow range, with its share price closing at HK$32.38. Over the past month, the stock edged up by 1%, reflecting investors’ cautious optimism. See our latest analysis for Chery Automobile. Momentum has been fairly muted for Chery Automobile, as this year’s modest 1.4% share price return suggests investors are still waiting to see if recent progress translates into stronger growth. After a flurry of updates earlier in the year, the...

BYD (SEHK:1211) just released new earnings showing sales have grown, but net income slipped compared to last year. This comes at a time when investors are questioning whether BYD can hold its lead in China’s crowded electric vehicle space. See our latest analysis for BYD. BYD's shares have been under pressure lately, with the stock sliding 11.7% over the past month as investors weigh up softening earnings and fierce competition from local EV makers. Despite this, the longer-term story remains...

Ascletis Pharma (SEHK:1672) has drawn attention this week by selecting ASC36, a once-monthly amylin receptor agonist, as its next clinical candidate for obesity treatment. The company intends to submit an IND for ASC36 to the U.S. FDA in 2026. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s run of pipeline news, including the latest about ASC36, has helped fuel market momentum, even as recent weeks saw some volatility. After an incredible year-to-date share price return of...

Innovent Biologics (SEHK:1801) just reported a 40% jump in product revenue for the third quarter, fueled by strong growth in both its established oncology portfolio as well as newer offerings like mazdutide and SINTBILO. See our latest analysis for Innovent Biologics. Innovent’s shares have been on a rollercoaster in recent weeks, but momentum is clearly building overall. The stock’s 1-year total shareholder return sits at an impressive 148%, even after some profit-taking since last month...

InnoCare Pharma recently announced two key milestones: the first patient was dosed in the clinical trial of their novel B7-H3 targeted antibody-drug conjugate (ADC) ICP-B794 in China, and positive phase I/II trial data for their next-generation pan-TRK inhibitor zurletrectinib in pediatric and adolescent patients were presented at the 2025 Congress of International Society of Paediatric Oncology. An important insight is that ICP-B794 targets a tumor-specific protein not yet addressed by any...

RemeGen (SEHK:9995) just grabbed the spotlight with new clinical data unveiled at the ESMO Congress and updated results for its myasthenia gravis therapy. The company also reported improved revenue and narrowing losses in its latest earnings report. See our latest analysis for RemeGen. These breakthroughs have put a fresh spotlight on RemeGen, and the market has taken notice. After a sharp sell-off in September, momentum has turned around in dramatic fashion. The stock’s 567.7% share price...

Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total...

China Hanking Holdings (SEHK:3788) has secured regulatory approval from Western Australia to commence dewatering at its Golden Pig gold mine. This approval unlocks the next phase of underground mining and could accelerate progress across the larger Cygnet gold project. See our latest analysis for China Hanking Holdings. China Hanking Holdings has been on a tear lately, with its 1-day share price return of 4.82% helping to erase some of the recent pullback. Despite some short-term volatility,...